HIV-1 Drug Resistance in Subjects with Advanced HIV-1 Infection in Whom Antiretroviral Combination Therapy Is Failing: A Substudy of AIDS Clinical Trials Group Protocol 388
We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in subjects in the AIDS Clinical Trials Group Protocol 388 (ACTG 388) who received lamivudine-zidovudine (or lamivudine-stavudine) and either indinavi...
Saved in:
Published in | Clinical infectious diseases Vol. 39; no. 4; pp. 552 - 558 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The University of Chicago Press
15.08.2004
University of Chicago Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in subjects in the AIDS Clinical Trials Group Protocol 388 (ACTG 388) who received lamivudine-zidovudine (or lamivudine-stavudine) and either indinavir, efavirenz-indinavir, or nelfinavir-indinavir. At VF, phenotypically susceptible HIV-1 was found in 55% of subjects in the nelfinavir-indinavir arm, compared with 22% in the indinavir arm (P = .006). Phenotypic resistance to lamivudine was less common in the efavirenz-indinavir arm (33% of subjects; P = .002) and the nelfinavir-indinavir arm (43%; P = .003), compared with the indinavir arm (78%). Isolated phenotypic resistance to efavirenz at VF occurred in HIV-1 recovered from 33% of subjects in the efavirenz-indinavir arm; 24% of the subjects had HIV-1 with both efavirenz and lamivudine resistance. Results of genotypic tests were similar. The lower frequency of resistance in the nelfinavir-indinavir arm likely reflects decreased drug exposure that is due to intolerance, which is consistent with the lower potency and tolerability of this combination in ACTG 388. The lower frequency of lamivudine resistance in the efavirenz-indinavir arm is consistent with reports in other studies of potent regimens. Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen. |
---|---|
AbstractList | We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in subjects in the AIDS Clinical Trials Group Protocol 388 (ACTG 388) who received lamivudine-zidovudine (or lamivudine-stavudine) and either indinavir, efavirenz-indinavir, or nelfinavir-indinavir. At VF, phenotypically susceptible HIV-1 was found in 55% of subjects in the nelfinavir-indinavir arm, compared with 22% in the indinavir arm (P = .006). Phenotypic resistance to lamivudine was less common in the efavirenz-indinavir arm (33% of subjects; P = .002) and the nelfinavir-indinavir arm (43%; P = .003), compared with the indinavir arm (78%). Isolated phenotypic resistance to efavirenz at VF occurred in HIV-1 recovered from 33% of subjects in the efavirenz-indinavir arm; 24% of the subjects had HIV-1 with both efavirenz and lamivudine resistance. Results of genotypic tests were similar. The lower frequency of resistance in the nelfinavir-indinavir arm likely reflects decreased drug exposure that is due to intolerance, which is consistent with the lower potency and tolerability of this combination in ACTG 388. The lower frequency of lamivudine resistance in the efavirenz-indinavir arm is consistent with reports in other studies of potent regimens. Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen. |
Author | Eshleman, Susan H. Fischl, Margaret A. Demeter, Lisa M. Hammer, Scott M. Erice, Alejo Ribaudo, Heather J. Hellmann, Nicholas S. |
Author_xml | – sequence: 1 givenname: Lisa M. surname: Demeter fullname: Demeter, Lisa M. email: lisa_demeter@urmc.rochester.edu organization: University of Rochester, New York, New York – sequence: 2 givenname: Heather J. surname: Ribaudo fullname: Ribaudo, Heather J. organization: Harvard School of Public Health, Boston, Massachusetts – sequence: 3 givenname: Alejo surname: Erice fullname: Erice, Alejo organization: University of Minnesota Medical School, Minneapolis – sequence: 4 givenname: Susan H. surname: Eshleman fullname: Eshleman, Susan H. organization: Johns Hopkins Medical Institutions, Baltimore, Maryland – sequence: 5 givenname: Scott M. surname: Hammer fullname: Hammer, Scott M. organization: Columbia University College of Physicians and Surgeons, New York, New York – sequence: 6 givenname: Nicholas S. surname: Hellmann fullname: Hellmann, Nicholas S. organization: ViroLogic, San Francisco, California – sequence: 7 givenname: Margaret A. surname: Fischl fullname: Fischl, Margaret A. organization: University of Miami School of Medicine, Florida |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15356820$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1u1DAURi1URH-AJ0DIbLoL2HEcO-xGKe1EFAHTgSI2luM4HQ-JPdhJy7wTD4mHjNoVYnUtneNPV_c7BgfWWQ3Ac4xeY8TzN1maUswfgSNMCUtyWuCD-EaUJxkn_BAch7BGCGOO6BNwGCWa8xQdgd_z6muC4Zkfb-BCBxMGaZWGxsKrsV5rNQR4Z4YVnDW3O9DAya9sG5lxdmder1wPZ3YwXg_e3RovO1i6vjZW_lWWK-3lZgurAM-l6Yy9eQtnu_wwjM0WuhbOqrMrWEZiVPy79EZ2AV54N27gJ-8Gp1wHCedPweM2Ev1sP0_Al_N3y3KeXH68qMrZZaKylAxJgXDbNgWRskWyIKyJlyl4yhukC8VkgVGEjHElca5kg1vOtaypRJKjDNU5OQGnU-7Gu5-jDoPoTVC666TVbgwizzllDJH_ipixAjOcPojKuxC8bsXGm176rcBI7AoUU4FRfLlPHOteNw_avrEovJqEeJx_h7yYnHUYnL-3Mkri5jjiZMKxbf3rHkv_Q-SMMCrm376LxfuSXi8-fBac_AEcqbkK |
CitedBy_id | crossref_primary_10_1111_j_1524_4733_2007_00170_x crossref_primary_10_15252_emmm_201708193 crossref_primary_10_1128_CMR_00017_07 crossref_primary_10_1517_14740338_6_2_147 crossref_primary_10_1086_422527 crossref_primary_10_1128_AAC_49_12_4884_4894_2005 |
Cites_doi | 10.1093/nar/28.1.346 10.1038/nm0796-753 10.1086/377311 10.1001/jama.283.18.2417 10.1128/AAC.44.4.920-928.2000 10.1089/088922200308800 10.1086/323604 10.1001/jama.283.2.205 10.1097/00002030-200103300-00009 10.1001/jama.283.2.229 10.1086/380509 10.1086/367987 |
ContentType | Journal Article |
Copyright | Copyright 2004 The Infectious Diseases Society of America 2004 by the Infectious Diseases Society of America 2004 |
Copyright_xml | – notice: Copyright 2004 The Infectious Diseases Society of America – notice: 2004 by the Infectious Diseases Society of America 2004 |
CorporateAuthor | AIDS Clinical Trials Group Protocol 388 |
CorporateAuthor_xml | – name: AIDS Clinical Trials Group Protocol 388 |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 H94 7X8 |
DOI | 10.1086/422518 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-6591 |
EndPage | 558 |
ExternalDocumentID | 10_1086_422518 15356820 10.1086/422518 4536681 ark_67375_HXZ_RKC5WRMQ_8 |
Genre | Research Support, U.S. Gov't, P.H.S Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI-38851 – fundername: NIAID NIH HHS grantid: U01-AI-48054 – fundername: NCRR NIH HHS grantid: RR-00044 – fundername: NIAID NIH HHS grantid: AI-27675 – fundername: NIAID NIH HHS grantid: AI-27658 – fundername: PHS HHS grantid: R29-34348 – fundername: NIAID NIH HHS grantid: U01-AI-46745 – fundername: NIAID NIH HHS grantid: AI-27661 |
GroupedDBID | --- ..I .2P .GJ .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABJS AABMN AABZA AACGO AACZT AAESY AAIYJ AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AASNB AAUQX AAVAP AAYOK ABBHK ABEUO ABIXL ABJNI ABLJU ABNHQ ABOCM ABPLY ABPTD ABQLI ABSAR ABTLG ABWST ABXSQ ABXVV ACGFO ACGFS ACIMA ACPRK ACUFI ACUTO ACYHN ADACV ADBBV ADEIU ADGZP ADHKW ADHZD ADIPN ADJQC ADORX ADQLU ADRIX ADRTK ADULT ADVEK ADYVW ADZLD ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIKOY AIMBJ AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQKUS AQVQM ASMCH ASPBG AVWKF AWCFO AXUDD AZFZN AZQFJ BAWUL BAYMD BCRHZ BEYMZ BGYMP BHONS BSCLL BTRTY BVRKM BYORX C1A C45 CASEJ CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DNJUQ DOOOF DPORF DPPUQ DU5 DWIUU D~K E3Z EBS EE~ EJD EMOBN ENERS ESX F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KSI KSN L7B M49 MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W8F X7H YAYTL YKOAZ YXANX ZA5 ZGI ~91 ~S- AANRK ALXQX AAUAY ABQNK ADQBN ATGXG IPSME CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 ADQXQ H94 7X8 |
ID | FETCH-LOGICAL-c423t-901ffd93aaf0a937d5189828d0e9c7a910d93778ca16cad1f88eab5a0a8040b63 |
ISSN | 1058-4838 |
IngestDate | Fri Aug 16 07:40:01 EDT 2024 Fri Aug 16 05:26:56 EDT 2024 Thu Sep 12 16:45:17 EDT 2024 Sat Sep 28 07:45:57 EDT 2024 Wed Sep 11 04:50:57 EDT 2024 Fri Feb 02 07:03:55 EST 2024 Sun Mar 31 11:38:42 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c423t-901ffd93aaf0a937d5189828d0e9c7a910d93778ca16cad1f88eab5a0a8040b63 |
Notes | ark:/67375/HXZ-RKC5WRMQ-8 istex:1E3B4D152F0593458EEBEA60A1EF03A3085DC498 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://academic.oup.com/cid/article-pdf/39/4/552/1050145/39-4-552.pdf |
PMID | 15356820 |
PQID | 17791712 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_66857703 proquest_miscellaneous_17791712 crossref_primary_10_1086_422518 pubmed_primary_15356820 oup_primary_10_1086_422518 jstor_primary_4536681 istex_primary_ark_67375_HXZ_RKC5WRMQ_8 |
PublicationCentury | 2000 |
PublicationDate | 2004-08-15 20040815 2004-Aug-15 |
PublicationDateYYYYMMDD | 2004-08-15 |
PublicationDate_xml | – month: 8 year: 2004 text: 20040815 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical infectious diseases |
PublicationTitleAbbrev | Clinical Infectious Diseases |
PublicationTitleAlternate | Clinical Infectious Diseases |
PublicationYear | 2004 |
Publisher | The University of Chicago Press University of Chicago Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
References | 15356821 - Clin Infect Dis. 2004 Aug 15;39(4):559-60 (2_38409338) 2003; 188 Descamps (10_6431865) 2000; 283 Kozal (11_16271861) 1996; 2 Havlir (9_6431868) 2000; 283 Petropoulos (3_6515243) 2000; 44 Hirsch (1_10315595) 2000; 283 Becker-Pergola (4_10327682) 2000; 16 (8_38492773) 2003; 187 Shafer (12_6399276) 2000; 28 Alexander (13_11123430) 2001; 15 (14_38420572) 2001; 184 (6_38565573) 2004; 189 |
References_xml | – volume: 28 start-page: 346 issn: 0305-1048 issue: 1 year: 2000 ident: 12_6399276 publication-title: Nucleic Acids Research doi: 10.1093/nar/28.1.346 contributor: fullname: Shafer – volume: 2 start-page: 753 issn: 1078-8956 issue: 7 year: 1996 ident: 11_16271861 publication-title: Nature medicine doi: 10.1038/nm0796-753 contributor: fullname: Kozal – volume: 188 start-page: 625 issn: 0022-1899 issue: 5 year: 2003 ident: 2_38409338 publication-title: Journal of Infectious Diseases doi: 10.1086/377311 – volume: 283 start-page: 2417 issn: 0098-7484 issue: 18 year: 2000 ident: 1_10315595 publication-title: JAMA doi: 10.1001/jama.283.18.2417 contributor: fullname: Hirsch – volume: 44 start-page: 920 issn: 0066-4804 issue: 4 year: 2000 ident: 3_6515243 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.44.4.920-928.2000 contributor: fullname: Petropoulos – volume: 16 start-page: 807 issn: 0889-2229 issue: 8 year: 2000 ident: 4_10327682 publication-title: AIDS research and human retroviruses doi: 10.1089/088922200308800 contributor: fullname: Becker-Pergola – volume: 184 start-page: 983 issn: 0022-1899 issue: 8 year: 2001 ident: 14_38420572 publication-title: Journal of Infectious Diseases doi: 10.1086/323604 – volume: 283 start-page: 205 issn: 0098-7484 issue: 2 year: 2000 ident: 10_6431865 publication-title: JAMA doi: 10.1001/jama.283.2.205 contributor: fullname: Descamps – volume: 15 start-page: 601 issn: 0269-9370 issue: 5 year: 2001 ident: 13_11123430 publication-title: AIDS (London, England) doi: 10.1097/00002030-200103300-00009 contributor: fullname: Alexander – volume: 283 start-page: 229 issn: 0098-7484 issue: 2 year: 2000 ident: 9_6431868 publication-title: JAMA doi: 10.1001/jama.283.2.229 contributor: fullname: Havlir – volume: 189 start-page: 51 issn: 0022-1899 issue: 1 year: 2004 ident: 6_38565573 publication-title: Journal of Infectious Diseases doi: 10.1086/380509 – volume: 187 start-page: 687 issn: 0022-1899 issue: 4 year: 2003 ident: 8_38492773 publication-title: Journal of Infectious Diseases doi: 10.1086/367987 |
SSID | ssj0011805 |
Score | 1.8245394 |
Snippet | We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in... |
SourceID | proquest crossref pubmed oup jstor istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 552 |
SubjectTerms | Acquired Immunodeficiency Syndrome - drug therapy Adult AIDS Antiretroviral Therapy, Highly Active - methods Antiretrovirals Antivirals Clinical trials Drug resistance Drug Resistance, Viral - physiology Female Genetic mutation Genotype HIV 1 HIV Infections - drug therapy HIV Infections - metabolism HIV Reverse Transcriptase - blood HIV Reverse Transcriptase - genetics HIV-1 - drug effects HIV-1 - enzymology HIV-1 - genetics HIV-1 - physiology HIV/AIDS Human immunodeficiency virus 1 Humans Indinavir - administration & dosage Indinavir - metabolism Lamivudine - administration & dosage Lamivudine - metabolism Male Memory interference Nelfinavir - administration & dosage Nelfinavir - metabolism Phenotype Stavudine - administration & dosage Stavudine - metabolism Treatment Failure Virology Viruses Zidovudine - administration & dosage Zidovudine - metabolism |
Title | HIV-1 Drug Resistance in Subjects with Advanced HIV-1 Infection in Whom Antiretroviral Combination Therapy Is Failing: A Substudy of AIDS Clinical Trials Group Protocol 388 |
URI | https://api.istex.fr/ark:/67375/HXZ-RKC5WRMQ-8/fulltext.pdf https://www.jstor.org/stable/4536681 https://www.ncbi.nlm.nih.gov/pubmed/15356820 https://search.proquest.com/docview/17791712 https://search.proquest.com/docview/66857703 |
Volume | 39 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FVkK8II5CU47uA-LFMrJjr9fmLcohmyZFFJdGvFjrSw00DkocCfE7-Bn8SGYvx6FUHC9WZI82cebb2dnZb2YQeuFT6js-S80sp8x0mWObKesR0yFumcMWo6QWTxSennrhuftmRmadzvcWa2lTp6-yb7_NK_kfrcI90CvPkv0HzTaDwg34DPqFK2gYrn-l4zD6YNrGcLURDDruCfJpOq-4OfgkaBoizNrX5_xSPlL8K8FxvLhcLngFAbB8NY8urEQwYQH7ZYmMWFYdMKK1MWbzK5Ue3RcGR9ej7kfD98ZAp1jG4sV1lGu1rJeANcORbfWaoghaWpPBNmt9VrTtdF8sCtU2ZGK0qm2nbJOLAG_YxLhHunl9g8fR-vKq0NHdcCe24fJgrczuVObYIiLc6bfttSx-pHDptowvkbVw1TpOZEn4a0uEJU6sXLBjyvDv1OA-fZuMzyeTJB7N4ltov0cDwrf0w-ikOZuyfUGMbX5bq2OVHHXHxdnns_WrZrv-kkZ5bTcjvJr4HrqrtiO4L7F1H3WK6gG6PVWEi4foh4AM5hDDW4jheYU1xDCHGNYQw1K-gRiX5BDDuxDDLYhhBTEcrbGC2GvcxxpgeFliDjCsIYMlwLAAGNYAwwCwA3Q-HsWD0FQNPswMvPiaU4PKMg8cxkqLgZ-cw58X-D0_t4ogoww8WXgIxiRjtpex3C59v2ApYRbzYe1JPecR2quWVXGIcOqVtgMjpF5QujSlKfi9buA4vK1LYGeki461TpIvso5LIvgXvpdIrXXRS6Gq5jFbfeasR0qScPYxOTsZkIuz6bsEBA-ELhtBlzie59tddATvfePox1rlCRhwfirHqgImV2JTGtjU7t0sAYMTCitzFz2WWNl-B3GIBz780R9Hf4LubCfYU7RXrzbFM3Cn6_S5QPdPzDjJTw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-1+Drug+Resistance+in+Subjects+with+Advanced+HIV-1+Infection+in+Whom+Antiretroviral+Combination+Therapy+Is+Failing%3A+A+Substudy+of+AIDS+Clinical+Trials+Group+Protocol+388&rft.jtitle=Clinical+infectious+diseases&rft.au=Demeter%2C+L+M&rft.au=Ribaudo%2C+HJ&rft.au=Erice%2C+A&rft.au=Eshleman%2C+SH&rft.date=2004-08-15&rft.issn=1058-4838&rft.volume=39&rft.issue=4&rft.spage=552&rft.epage=558&rft_id=info:doi/10.1086%2F422518&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |